BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 28960584)

  • 1. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex.
    Kaan HYK; Chan SW; Tan SKJ; Guo F; Lim CJ; Hong W; Song H
    Sci Rep; 2017 May; 7(1):2035. PubMed ID: 28515457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
    Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
    Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of YAP recognition by TEAD4 in the hippo pathway.
    Chen L; Chan SW; Zhang X; Walsh M; Lim CJ; Hong W; Song H
    Genes Dev; 2010 Feb; 24(3):290-300. PubMed ID: 20123908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
    Niu RJ; Zheng QC; Zhang HX
    J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
    Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
    J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.
    Hau JC; Erdmann D; Mesrouze Y; Furet P; Fontana P; Zimmermann C; Schmelzle T; Hofmann F; Chène P
    Chembiochem; 2013 Jul; 14(10):1218-25. PubMed ID: 23780915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
    Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
    Elife; 2017 Apr; 6():. PubMed ID: 28430104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
    Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
    Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational Design and Intramolecular Cyclization of Hotspot Peptide Segments at YAP-TEAD4 Complex Interface.
    Zhang D; He D; Pan X; Liu L
    Protein Pept Lett; 2020; 27(10):999-1006. PubMed ID: 32286937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into the YAP and TEAD complex.
    Li Z; Zhao B; Wang P; Chen F; Dong Z; Yang H; Guan KL; Xu Y
    Genes Dev; 2010 Feb; 24(3):235-40. PubMed ID: 20123905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
    Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
    J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.